Last reviewed · How we verify
NCT06567613
Validation of a Swiss German Language Test for Children
trial testing Speech test in Hearing Loss in 180 participants. Completed in 31 December 2025.
31 December 2025
Quick facts
| Lead sponsor | Insel Gruppe AG, University Hospital Bern |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 180 |
| Start date | 10 October 2024 |
| Primary completion | 31 December 2025 |
| Estimated completion | 31 December 2025 |
| Sites | 4 locations across Switzerland |
Drugs / interventions tested
- Speech test
Conditions studied
- Hearing Loss — all drugs for Hearing Loss →
Sponsor
Insel Gruppe AG, University Hospital Bern
Who can join
Adults 4 to 6, any sex, with Hearing Loss. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of this study is to validate a Swiss German children's language test. Standard values for the speech intelligibility of Swiss German monosyllables and disyllables for children with normal hearing aged 4-6 years are recorded.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Development of a Speech Intelligibility Test for Children in Swiss German Dialects.
Schmid C, Blatter S, Seifert E, Aebischer P, et al · · 2026 · PMID 41718333 · DOI 10.3390/audiolres16010016
Verify or expand the search:
- PubMed search for NCT06567613
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Hearing Loss
Currently open trials in the same condition.
- NCT07176936 — Improving Speech in Noise Using Noninvasive Stimulation · NA · recruiting
- NCT07506408 — Randomised Study of Web-Based Auditory Training With Varying Perceptual and Cognitive Demands on Training Gains and Gene · NA · recruiting
- NCT07218913 — Testing the Addition of Pedmark to Cisplatin Chemotherapy for Reducing Drug-Induced Ear Damage in Men With Stage II-III · Phase 1 · recruiting
- NCT07414329 — Efficacy and Effectiveness of an Investigational Behind-the-Ear Hearing Device Kit · NA · recruiting
- NCT06930560 — HEARS-NPS: Addressing Hearing Loss as a Common Unmet Contributor of Neuropsychiatric Symptoms · NA · recruiting
Other Insel Gruppe AG, University Hospital Bern trials
Trials by the same sponsor.
- NCT06546384 — GLP-1 RA on Alcohol Consumption, Metabolism and Liver Parameters in Patients With Obesity and Fatty Liver Disease · NA · not yet recruiting
- NCT07524049 — Giving Children a Voice in Paediatric Anaesthesia · not yet recruiting
- NCT07415668 — Motor Eloquent Navigated Transcranial Magnetic Stimulation for Radiosurgery Planning · NA · not yet recruiting
- NCT07478536 — Stockholm3 Test Validation in Men on Active Surveillance in Switzerland (CHAS3 Trial) · not yet recruiting
- NCT07201506 — Real-Time Intracardiac Echocardiography for Ventricular Arrhythmia Ablation · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06567613 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Insel Gruppe AG, University Hospital Bern
- Last refreshed: 7 January 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06567613.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing